Literature DB >> 21519998

Full-dose capecitabine with local radiotherapy: one of the treatment options for inoperable T4 breast cancer.

Hisako Hirowatari1, Kumiko Karasawa, Hiromi Izawa, Kana Ito, Keisuke Sasai, Tomohisa Furuya, Shuichi Ozawa, Atsushi Arakawa, Gotaro Orihata, Mitsue Saito.   

Abstract

A 48-year-old woman presented with a 15-cm diameter tumor in her left breast with fixation to the chest wall and palpable axillary lymph nodes. Pathology study showed pure-type mucinous carcinoma. Pretreatment staging investigations showed multiple lung metastases, which resulted in the diagnosis of T4N2M1 breast cancer. Four cycles of cyclophosphamide 700 mg/m(2)/epirubicin 70 mg/m(2) (CE) were performed initially, but the tumors decreased only within the treatment response criteria of stable disease (SD). The second regimen of docetaxel could not continue due to drug allergy. Two more cycles of CE did not improve the situation. Then, treatment was continued with full-dose capecitabine with local radiotherapy. She received radiotherapy to the left breast and axillary region with 60 Gy/30 fractions/6 weeks and concomitant capecitabine 2400 mg/body twice daily for 21 days; the cycles were repeated every 28 days. After radiotherapy, tumors decreased in size, and the skin ulceration disappeared. She continued to receive capecitabine on the same schedule. She now has no palpable tumor in her left breast and no tumor in the axilla or lung on CT. She is alive and well 6 years after radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519998     DOI: 10.1007/s11604-010-0537-7

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  6 in total

1.  A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer.

Authors:  Maria de Fátima Dias Gaui; Gilberto Amorim; Roberto Alfonso Arcuri; Guilherme Pereira; Denise Moreira; Célia Djahjah; Irene Biasoli; Nelson Spector
Journal:  Am J Clin Oncol       Date:  2007-02       Impact factor: 2.339

2.  Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse.

Authors:  Hajime Hikino; Takako Yamada; Kanta Johbara; Nobuhiko Obayashi; Nobuhiro Ozaki
Journal:  Breast       Date:  2005-07-07       Impact factor: 4.380

3.  X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.

Authors:  N Sawada; T Ishikawa; F Sekiguchi; Y Tanaka; H Ishitsuka
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

4.  Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma.

Authors:  Sarah A Thurman; Stuart J Schnitt; James L Connolly; Rebecca Gelman; Barbara Silver; Jay R Harris; Abram Recht
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-05-01       Impact factor: 7.038

5.  Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer.

Authors:  Kumiko Karasawa; Kuniaki Katsui; Kaori Seki; Mari Kohno; Nahoko Hanyu; Sachiko Nasu; Hiroyuki Muramatsu; Katsuya Maebayashi; Norio Mitsuhashi; Shunsuke Haga; Tsunehito Kimura; Isamu Takahashi
Journal:  Breast Cancer       Date:  2003       Impact factor: 4.239

6.  Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients.

Authors:  Cyrus Chargari; Youlia M Kirova; Véronique Diéras; Pablo Castro Pena; Pablo Castro Pena; Francois Campana; Paul H Cottu; JeanYves Pierga; Alain Fourquet
Journal:  J Neurooncol       Date:  2009-01-25       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.